The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018–2024
This post-marketing safety study evaluated the co-administration of recombinant zoster vaccine (RZV, Shingrix) and influenza vaccines (HD-IIV/aIIV/RIV) in adults aged ≥ 65 years using U.S. VAERS data (2018–2024). Among 791 adverse event (AE) reports analyzed via empirical Bayesian data mining and cl...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2525603 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!